Physiomics Regulatory News (PYC)

31 August 2010

Physiomics plc

("Physiomics" or "the Company")

Physiomics announces intent to enter a joint services alliance with Jubilant Biosys

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has executed non legally binding heads of terms relating to a joint services alliance with Jubilant Biosys Limited ("JBL"), based in Bangalore, an integrated Drug Discovery and Development solutions provider. JBL is a subsidiary of Jubilant Organosys Limited, headquartered in Noida, New Delhi. Under the terms of the proposed co-operation Physiomics and JBL intend to collaborate in the field of oncology providing their services jointly to pharmaceutical and biotechnology companies. It is anticipated that any final agreement would be completed by the third quarter of 2010.

This unique service offering would combine Physiomics' modelling expertise in biological processes to predict the effects of anti-cancer drugs in living systems and JBL's expertise in oncology preclinical in vitro and in vivo assays. The main deliverables of the offering would be to provide client companies with the optimal combinations of standard of care agents and schedules for their anti-cancer drugs.

A further announcement will be made if the final agreement is executed.

Dr Christophe Chassagnole, COO of Physiomics, said

'The intended partnership with a world class Drug Discovery & Development solutions provider will provide an innovative integrated service offering to existing and potential partners of both companies. The combination of "dry" and "wet" experiments will enable a faster and more efficient way to develop pre-clinical anti-cancer drug candidates.'

Enquiries:

Physiomics plc

Dr Christophe Chassagnole, COO

+44 (0)1865 784980

WH Ireland Limited

Katy Mitchell

+44 (0) 161 832 2174

Information on Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. As 80-90 per cent of all clinical drug candidates fail to reach the market, estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The models are used to optimise compound design, as well as to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com